In the context of COVID-19, Vlaar et al. reported the first RCT showing increased survival of COVID-19 patients, leading to “urgent” FDA approval for vilobelimab (C5a-targeted monoclonal antibody) treatment in critically ill COVID-19 patients.19 Nevertheless, there remains an urgent need for novel C5a-targeted therapeutics to alleviate the economic burden of the extremely costly drugs on the market today and increase patient accessibility. This evidence concerns the gene C5AR1 and COVID-19.